Nexstim PLC · OMXHEX:NXTMH
Nexstim — Swedbank Finnish Life Science Event 2023
11 slides from Nexstim's conference presentation, Mar 22, 2023
Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim- Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc Swedbank Finnish Life Science Event, Helsinki, 22 Mar 2023 Nexstim Oyj
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating growth-oriented medical technology company. MISSION VISION VALUES • We enable personalized and • With our technological know-how • Science and clinical evidence effective therapies and and superior services, • Financial success diagnostics for c
Slide 4: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. 1 2 3 Technological Healthcare cost Aging population development in pressures healthcare • Population aging and a • Technological • The need for more significan
Slide 5: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS Diagnostics (Navigated Over 210 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® Over 60 Depression CE marked with existing Therapy (Navigated system
Slide 6: Business and Financial Summary 2022
Nexstim Business and Financial Summary 2022 • Nexstim’s historically best year measured by net sales, • Diagnostics Business (NBS) net sales decreased by -7.7% in operating profit and result for the period 2022 to EUR 3.4M (2021: EUR 3.7M) and the Therapy Business (NBT®) net sales grew by 126.8 % in
Slide 7: Financial Progress 2018-2022
Nexstim Financial Progress 2018-2022 Financial Progress (EUR thousands) 12 000 10 000 9 527 8 000 6 398 6 000 4 114 4 000 3 348 2 672 2 000 1 002 840 - -2 000 -1 452 -2 109 -2 725 -4 000 -3 333 -6 000 -6 316 -6 193 -6 517 -6 682 -8 000 2018 2019 2020 2021 2022 Net Sales Operating Result Cashflow fro
Slide 8: 2022 Key Financials
2022 Key Financials Key Financials of the Group Total net sales 9.5M€ +48.9% 1–12/2022 1–12/2021 • Adj. comparable EUR in thousands Change-% 12 months 12 months net sales 6.0M€ +9.2% • NBS net sales 3.4M€ -7.7% Net Sales 9,526.7 6,397.5 48.9 • NBT net sales 6.1M€ +126.8% Gross margin 8,285.9 5,262.0
Slide 9: Key Strategic Objectives 2023
Nexstim Key Strategic Objectives 2023 1 2 3 Profitable comparable net The launch of the new Expanding the network of sales growth, leading to a NBS 6 product, enabling Nexstim exclusive positive EBITDA easy-to-use systems and collaboration clinics (operating result before the use of future primarily
Slide 10: NBS 6 - future of the Nexstim system
NBS 6 – future of the Nexstim system Developing and lauching a new product generation is an essential part of Nexstim’s work during the 2020-2024 strategy period • The NBS 6 is a new combined system that has been built 1 on Nexstim’s unique, clinically established technology. • The modular product d
Slide 11: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim @NexstimTMS Nexstim Oyj Nexstim Plc Public Presentation 11